Table 4 Characteristics of eligible trials for Ewing sarcoma only

Hawkins et al, Med Pediatric Oncol, 34 (5): 328-37 [33]

Myeloablative therapy followed by HSCT.

3-year EFS 36%

Kolb et al, J Clin Oncol, 21 (18): 3423-30 [75]

7 cycles of chemotherapy consisted of Cyclo, Doxo, Vin, Ifos and Etop

29 (43%) CR, 13 (19%) PD or SD

Meyer et al, Sarcoma, 7 (1): 13-7 [76]

Doc thrice weekly for a maximum of six cycles.

1 (14%) PR, 2 (28%) SD

Bernstein et al, J Clin Oncol, 24 (1): 152-9 [77]

High-dose induction therapy followed by window period. Randomization between topo, topo + cyclo or no treatment. No window treatment patients received Amifostine

45 (43%) CR, 41 (39%) PR, 14 (14%) SD

Womer et al, ASCO abstract

Vin, Doxo and Cyclo alternating with Ifos and Etop, for 14 cycles. Regimen A: 3 weeks cycle, regimen B: 2 week cycle. Primary tumor treatment was scheduled to begin week 13.

EFS at a median of 3 years was 65% in Regimen A and 76% in Regimen B.

Rosenthal et al, Bone Marrow Transplantation, 42: 311-8 [78]

HDT followed by HSCT.

3-year EFS 47%, 3-year OS 45%

DuBois et al, Pediatric Blood Cancer, 52 (3): 324-7 [79]

Cytarabine.

1 (10%) SD

Casey et al, Pediatric Blood Cancer, 53 (6): 1029-34 [80]

Irinotecan and Temozolomide.

5 (25%) CR, 7 (36%) PR

Olmos et al, Lancet Oncol, 11: 129-35 [56]

A subgroup of Ewing Sarcoma patients were treated with Figitumumab

1 (6%) CR, 1 (6%) PR, 6 (37%) SD